Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 5/20 | 0.61 |
| ▸ | ADORA1 | P30542 | 5/20 | 0.61 |
| ▸ | HPGD | P15428 | 1/20 | 0.57 |
| ▸ | ADORA2A | P29274 | 4/20 | 0.56 |
| ▸ | ADORA2B | P29275 | 3/20 | 0.56 |
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
| ▸ | TP53 | P04637 | 1/20 | 0.55 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31685564 | 0.89 | MEN1 (0.51) | ADORA3ADORA1HPGDADORA2AADORA2B | |
| SCHEMBL20548039 | 0.87 | ADORA2A (0.53) | ADORA3ADORA1HPGDADORA2AADORA2B | |
| SCHEMBL6365742 | 0.86 | HPGD (0.52) | ADORA3ADORA1HPGDADORA2AADORA2B | |
| SCHEMBL31685735 | 0.86 | ADORA1 (0.52) | ADORA3ADORA1ADORA2AADORA2B | |
| SCHEMBL31685449 | 0.85 | IMPDH2 (0.62) | ADORA1 | |
| SCHEMBL62505 | 0.85 | CYP2C19 (0.62) | ADORA3ADORA1HPGDADORA2AADORA2B | |
| SCHEMBL18844803 | 0.85 | CYP2C19 (0.62) | ADORA3ADORA1HPGDADORA2AADORA2B | |
| SCHEMBL14931005 | 0.85 | CYP2C19 (0.62) | ADORA3ADORA1HPGDADORA2AADORA2B | |
| SCHEMBL343478 | 0.85 | CYP2C19 (0.62) | ADORA3ADORA1HPGDADORA2AADORA2B | |
| SCHEMBL18512921 | 0.85 | CYP2C19 (0.62) | ADORA3ADORA1HPGDADORA2AADORA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250289840-A1 | RNA STABILIZING SUBSTANCES AND METHODS OF USE | TEAM MEDICAL, LLC | 2025-09-18 | — | — | US | disclosed |
| US-20240011031-A1 | COMPOSITIONS COMPRISING A NUCLEASE AND USES THEREOF | Arbor Biotechnologies, Inc. (US) | 2024-01-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250289840-A1 | RNA STABILIZING SUBSTANCES AND METHODS OF USE | SYNCRIP, SNRPA, RNASE1 | ADORA3 655/4885ADORA1 935/4885HPGD 4461/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.